Ayla Güven

Ayla Güven

Auto-generated profile, based on publicly available information

Ayla Güven

Pediatric Endocrinology Clinic, Göztepe Education and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
IBIrina Bacila
Irina Bacila
NFNicole Freeman
Nicole Freeman
EDEleni Daniel
Eleni Daniel
MSMarija Sandrk
Marija Sandrk
JBJillian Bryce
Jillian Bryce
NKNils P Krone
Nils P Krone
Objective: Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. Design: This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. Methods: Data were collected from 461 patients aged 0–18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 and 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement were analyzed from 4174 patient visits. Results: The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose (median with interquartile range) of 12.0 (10.0–14.5) mg/m2/day at age 1–8 years and the highest dose of 14.0 (11.6–17.4) mg/m2/day at age 12–18 years. Glucocorticoid doses decreased after 2010 in patients 0–8 years (P < 0.001) and remained unchanged in patients aged 8–18 years. Fludrocortisone was used in 92% of patients, with relative doses decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone replacement. Conclusions: Data from the I-CAH Registry suggests international variations in hormone replacement therapy, with a tendency to treatment with high doses in children.

1 January 2007 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
AGA. Güven
A. Güven
ÖGÖ. Gülümser
Ö. Gülümser
TÖT. Özgen
T. Özgen
Prolonged application of topical steroids transiently suppresses the hypothalamic-pituitary-adrenal axis (HPA). Infants who are exposed to topical corticosteroids have greater risk for Cushing's syndrome or adrenocortical insufficiency caused by suppression of the HPA axis because glucocorticoids are highly absorbed through the diaper area. Here, we report six infants (four girls, two boys) aged between 3 and 8 months who were exposed to potent topical corticosteroids (clobetasol propionate and diflucortolone valerate) by the mother's application without prescription. We examined the HPA axis and other side effects of the potent glucocorticoid therapy in these infants. After stopping the topical corticosteroid, serum AST, ALT, lipids, morning cortisol and ACTH levels were measured. A low dose ACTH stimulation test was carried out. Hydrocortisone was started for the prevention of glucocorticoid withdrawal syndrome and the dose was gradually decreased. Abdominal ultrasonography was performed to investigate hepatosteatosis. The ACTH stimulation test showed suppression of the HPA axis in these infants. Hepatomegaly was found in all infants and three of them had hepatosteatosis. Liver transaminase levels were elevated in five infants. Five patients have been followed for 6-14 months. One infant died due to generalized Cytomegalovirus infection. We emphasize that physicians should be alert for the dangerous side-effects of topical steroids and they should avoid long-term use. Furthermore, parents should be informed about the side-effects when topical steroid treatment is chosen.

2 February 2005 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
AGAyla Güven
Ayla Güven
PCPeyami Cinaz
Peyami Cinaz
ABAysun Bideci
Aysun Bideci

1 December 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
AAAyşehan Akıncı
Ayşehan Akıncı
DTDoğa Türkkahraman
Doğa Türkkahraman
ITİbrahim Tekedereli
İbrahim Tekedereli
LÖLeyla Özer
Leyla Özer
BEBahri Evren
Bahri Evren
OEOya Ercan
Oya Ercan
Non syndromic monogenic obesity is a rare cause of early onset severe obesity in the childhood period. This form may not be distinguishable from other forms of severe obesity without genetic analysis, particularly if patients do not exibit any physical abnormalities or developmental delay. The aim of this study was to screen 41 different obesity-related genes in children with non-syndromic early onset severe obesity. Children with severe (body mass index-standard deviation score >3) and early onset (<7 years) obesity were screened by next-generation sequencing based, targeted DNA custom panel for 41 known-obesity-related genes and the results were confirmed by Sanger technique. Six novel variants were identified in five candidate genes in seven out of 105 children with severe obesity; two in SIM1 (p.W306C and p.Q36X), one in POMC (p.Y160H), one in PCSK1 (p.W130G fs Ter8), two in MC4R (p.D126E) and one in LEPR (p.Q4H). Additionally, two previously known variations in MC4R were identified in four patients (p.R165W in three, and p.V166I in one). We identified six novel and four previously described variants in six obesity-related genes in 11 out of 105 childrens with early onset severe obesity. The prevalence of monogenic obesity was 10.4% in our cohort.

5 May 2011 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
AGA Guven
A Guven
NCN Cebeci
N Cebeci
ADA Dursun
A Dursun
EAEh Aktekin
Eh Aktekin
MBM R Baumgartner
M R Baumgartner
BFB Fowler
B Fowler
Guven A, Cebeci N, Dursun A, Aktekin EH, Baumgartner MR, Fowler B. Methylmalonic acidemia mimicking diabetic ketoacidosis in an infant. Methylmalonic acidemia (MMA) is an inherited organic acidemia usually present with recurrent episodes of acute illness. A typical episode is ushered in with ketonuria and vomiting, followed by acidosis, dehydration, and lethargy, leading, in the absence of aggressive treatment, to coma and death. We report an infant with MMA presented with diabetes symptoms. A 13‐month‐old girl complained of polydipsia, diuresis, and loss of weight. She had clinical signs of diabetic ketoacidosis such as dehydration, deep sighing respiration, smell of ketones, lethargy, and vomiting. Laboratory analysis showed hyperglycemia with acidosis and ketonuria. She was treated with parenteral fluid, electrolyte, and insulin infusion. Two days after her discharge, after having a meal rich in protein, she was brought unconscious with hepatomegaly, severe acidosis, ketonuria, and mild hyperammonemia. The absence of hyperglycemia and the presence of neurologic findings suggested organic acidemia. MMA was diagnosed because of methylmalonic aciduria and elevated C3 carnitine esters. Cranial magnetic resonance imaging (MRI) showed increased uptake of radiocontrast material in the basal ganglia bilaterally. A homozygous mutation in exon 4 of the MMAA gene was found in mutation analysis and confirmed the diagnosis of cblA‐deficient MMA. Neurologic regression was improved with treatment of low‐protein diet, vitamin B12, and l‐carnitine. In patients born to consanguineous parents who admit during infancy with severe acidosis refractory to treatment, organic acidemias should be kept in mind, even they have high blood glucose. The definitive diagnosis is important because it may allow a specific treatment and a favorable evolution to prevent the sequelae.

22 September 2017 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
SHSuna Hancili
Suna Hancili
ABAmélie Bonnefond
Amélie Bonnefond
JPJulien Philippe
Julien Philippe
EVEmmanuel Vaillant
Emmanuel Vaillant
FGFranck De Graeve
Franck De Graeve
MVMartine Vaxillaire
Martine Vaxillaire